Carcinoid Tumor: Clinical Trials

104 trials for Carcinoid Tumor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

48 completed, 13 unknown, 11 terminated, 10 recruiting. 47 Phase 2, 20 Phase 1, 11 Phase 3, 5 Not applicable, 2 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 247Completed 28, Terminated 5, Unknown 5, Active not recruiting 3, Recruiting 3, Withdrawn 3
Phase 120Completed 9, Unknown 4, Terminated 3, Recruiting 2, Withdrawn 2
Phase 311Completed 4, Active not recruiting 2, Terminated 2, Recruiting 1, Unknown 1, Withdrawn 1
Not applicable5Completed 2, Active not recruiting 1, Recruiting 1, Unknown 1
Early Phase 12Active not recruiting 1, Withdrawn 1
Phase 42Completed 2

Follow Carcinoid Tumor: new trials by email Literature Review of Carcinoid Tumor trials Research Report on Carcinoid Tumor

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms
Somatostatin Analogue(s) - Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm
Phase 3RecruitingWashington University School of Medicine2402026-11-022026-11-06
CardioNETPOL National Registry of Carcinoid Heart Disease
Observational Registry of Carcinoid Heart Disease - Carcinoid Heart Disease, Neuroendocrine Tumors
Not yet recruitingNational Institute of Cardiology, Warsaw, Poland1202026-06-012026-03-04
Pharmaceutical Management in Targeted Radioligand Therapy
Cancer, Thyroid Cancer
RecruitingHospices Civils de Lyon6002026-01-092026-02-05
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RYZ401 - GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Phase 1RecruitingRayzeBio, Inc.1042025-12-032026-11-03
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Paltusotine, Placebo - Carcinoid Syndrome, Carcinoid
Phase 3Active not recruitingCrinetics Pharmaceuticals Inc.1412025-11-192026-10-15
IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4 - Peritoneal Mesothelioma, Gestational Trophoblastic Tumor
Phase 2Active not recruitingHospices Civils de Lyon272025-10-012026-06-25
ALG-LungCancerRegistry (SAFRO2202)
Observational Data Collection - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
RecruitingSociété Algérienne de Formation et de Recherche en Oncologie37502025-06-012025-09-16
Life Following Excision of Neuroendocrine Tumors
Neuroendocrine (NE) Tumors, Neuroendocrine Tumor GEP Grade 1-3
RecruitingSunnybrook Health Sciences Centre2462025-04-282025-05-20
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Everolimus 5 MG - Neuroendocrine Tumors, Progression
Phase 2RecruitingAC Camargo Cancer Center1002024-04-242024-06-25
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
177Lu-DOTATOC - Neuroendocrine Tumors, Carcinoid Tumor
Phase 2WithdrawnBritish Columbia Cancer Agency2023-01-152023-02-21
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Lu-177-DOTATATE, Olaparib, Ga dotatate scanning - Gastroenteropancreatico Tumors, Neuroendocrine Tumors
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)562022-10-032026-10-16
68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET
Neuroendocrine Tumor Carcinoid, Neuroendocrine Tumor of Pancreas
UnknownEuropean Institute of Oncology202022-05-122023-09-22
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Randomized: 40 mg Paltusotine, Randomized: 80 mg Paltusotine - Carcinoid Syndrome, Carcinoid
Phase 2CompletedCrinetics Pharmaceuticals Inc.362022-04-222026-03-19
Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease
Transcatheter Tricuspid Valved Stent Graft - Tricuspid Regurgitation, Tricuspid Valve Disease
Not applicableActive not recruitingQueen Mary University of London152022-04-062026-11-19
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RYZ101, Everolimus, Sunitinib - GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Phase 3Active not recruitingRayzeBio, Inc.3432022-03-242026-10-05
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Cabozantinib, Nivolumab - Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma
Phase 2RecruitingFox Chase Cancer Center1112022-01-212026-07-28
Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors
Telotristat Ethyl Oral Tablet - Neuroendocrine Tumors
Phase 2WithdrawnUniversity of Chicago2022-01-012021-12-17
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
PICO G2 4k - Cancer Pain, Visceral Pain
Not applicableRecruitingCedars-Sinai Medical Center3602021-10-052026-11-12
The Registry of Oncology Outcomes Associated With Testing and Treatment
Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P) - Adenocarcinoma, Adenocystic Carcinoma
CompletedTaproot Health1672021-05-052024-12-18
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
arginine/lysine - Gastroenteropancreatic Neuroendocrine Tumors
Phase 4CompletedAdvanced Accelerator Applications422021-01-252025-01-24

Showing 20 of 104. Sign in to see all of them.

Narrower conditions

Neuroendocrine Tumors (58)  ·  Adenoma, Islet Cell (15)  ·  Neoplasms (12)  ·  Neoplasm Metastasis (11)  ·  Serotonin Syndrome (11)  ·  Neuroblastoma (9)  ·  Pheochromocytoma (9)  ·  Paraganglioma (8)  ·  Carcinoma (7)  ·  Carcinoma, Neuroendocrine (7)  ·  Gastro-enteropancreatic neuroendocrine tumor (6)  ·  Carcinoid Heart Disease (5)  ·  Colorectal Neoplasms (5)  ·  Pancreatic Neoplasms (5)

Broader conditions

Neoplasms, Germ Cell and Embryonal (104)  ·  Neoplasms, Nerve Tissue (104)  ·  Neuroectodermal Tumors (104)  ·  Neoplasms by Histologic Type (103)  ·  Neoplasms, Glandular and Epithelial (103)  ·  Adenocarcinoma (101)  ·  Carcinoma (97)  ·  Neoplasms (92)  ·  Neuroendocrine Tumors (46)  ·  Neoplasms by Site (40)  ·  Endocrine System Diseases (33)  ·  Endocrine Gland Neoplasms (32)  ·  Digestive System Diseases (30)  ·  Digestive System Neoplasms (30)  ·  Pancreatic Diseases (27)

Interventions

Everolimus (10)  ·  Octreotide (7)  ·  lanreotide (6)  ·  gallium Ga 68 dotatate (5)  ·  pasireotide (5)  ·  Nivolumab (3)  ·  Sunitinib (3)  ·  cabozantinib (3)  ·  lutetium Lu 177 dotatate (3)  ·  Bevacizumab (2)  ·  Capecitabine (2)  ·  Erlotinib Hydrochloride (2)  ·  Ga(III)-DOTATOC (2)  ·  Temozolomide (2)  ·  fluorodopa F 18 (2)

Sponsors

Novartis Pharmaceuticals (8)  ·  Dana-Farber Cancer Institute (7)  ·  British Columbia Cancer Agency (4)  ·  H. Lee Moffitt Cancer Center and Research Institute (4)  ·  Hospices Civils de Lyon (3)  ·  Suez Canal University (3)  ·  CHU de Reims (2)  ·  Crinetics Pharmaceuticals Inc. (2)  ·  Ipsen (2)  ·  M.D. Anderson Cancer Center (2)  ·  RayzeBio, Inc. (2)  ·  Rutgers University (2)  ·  SCRI Development Innovations, LLC (2)  ·  Sue O'Dorisio (2)  ·  University of California, San Francisco (2)

Countries

United States (65)  ·  Canada (15)  ·  France (12)  ·  Italy (8)  ·  Poland (8)  ·  Germany (7)  ·  Netherlands (7)  ·  Spain (7)  ·  Belgium (6)  ·  Brazil (6)  ·  United Kingdom (6)  ·  Argentina (3)  ·  Czechia (3)  ·  Sweden (3)  ·  China (2)

Top investigators

Francois Benard, MD (3)  ·  Jonathan Strosberg, M.D. (3)  ·  David Spigel, M.D. (2)  ·  Jennifer Chan, MD, MPH (2)  ·  Nancy Gardner, PhD (2)  ·  Ye Yuan, MD (2)  ·  Ajaykumar Morani (1)  ·  Andreas Baumbach (1)  ·  Andrei Iagaru (1)  ·  Andrew Poklepovic, MD (1)  ·  Angela Lamarca (1)  ·  Aurel Perren, MD (1)

Results publications

PMID 18391430, PMID 19097774, PMID 22119496, PMID 22736724, PMID 23187897, PMID 23475104, PMID 23516312, PMID 24800725, PMID 25376618, PMID 26769865, PMID 27214300, PMID 28153957, PMID 28444114, PMID 29149611, PMID 29181270, PMID 30158287, PMID 30506283, PMID 30943124, PMID 31682550, PMID 31754316, PMID 31980466, PMID 32359091, PMID 32392558, PMID 32919526, PMID 33382891, PMID 33836153, PMID 34990208, PMID 35114169, PMID 35361487, PMID 35588692, PMID 35680043, PMID 35777186, PMID 35835611, PMID 36395401, PMID 36748723, PMID 37074571, PMID 37838323, PMID 38652200, PMID 38753757, PMID 39453770, PMID 39500789, PMID 39834129, PMID 39945192, PMID 39979665, PMID 40121391, PMID 41920388

NIH funding

2004 (1), 2005 (1), 2015 (1), 2019 (1), R01CA252211 (1)